01
Cash & equivalents decreased 13.4%
Cash & equivalents changed -13.4% from the comparable as-filed period.
$3.0M→$2.6MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTKairos Pharma, LTD.'s latest supported as-filed period reports net income of -$1.4M, 2.4% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -13.4% from the comparable as-filed period.
Net income changed +2.4% from the comparable as-filed period.
Operating income changed +2.7% from the comparable as-filed period.
Research & development changed +24.8% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
KAPA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001493152-26-039695SEC ↗10-QAug 12, 2026Period Jun 30, 20260001493152-26-037355SEC ↗8-KJul 22, 2026Period Jul 16, 20260001493152-26-034185SEC ↗8-KJul 15, 2026Period Jul 15, 20260001493152-26-033289SEC ↗8-KJun 30, 2026Period Jun 29, 20260001493152-26-031328SEC ↗8-KJun 4, 2026Period Jun 4, 20260001493152-26-027200SEC ↗8-KMay 18, 2026Period May 18, 20260001493152-26-024082SEC ↗10-QTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 8, 2025Filed Dec 30, 2025 | Bhowmick NeilChief Scientific Officer | Grant Or AwardDirect | 171,756 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001493152-26-022796